Savior Lifetec
Market Cap
NT$8.3b
Last Updated
2021/01/23 08:43 UTC
Data Sources
Company Financials +
Executive Summary
Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with acceptable track record.
Share Price & News
How has Savior Lifetec's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4167 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 4167's weekly volatility (4%) has been stable over the past year.
Market Performance
7 Day Return
-7.2%
4167
-2.4%
TW Pharmaceuticals
2.5%
TW Market
1 Year Return
31.9%
4167
28.2%
TW Pharmaceuticals
31.6%
TW Market
Return vs Industry: 4167 exceeded the TW Pharmaceuticals industry which returned 28.2% over the past year.
Return vs Market: 4167 matched the TW Market which returned 31.6% over the past year.
Shareholder returns
| 4167 | Industry | Market | |
|---|---|---|---|
| 7 Day | -7.2% | -2.4% | 2.5% |
| 30 Day | -18.9% | -10.2% | 11.8% |
| 90 Day | -15.5% | -21.6% | 22.9% |
| 1 Year | 31.9%31.9% | 30.4%28.2% | 36.3%31.6% |
| 3 Year | -4.5%-4.5% | 34.3%27.1% | 59.7%41.8% |
| 5 Year | 22.7%21.2% | 6.4%-1.6% | 136.2%94.8% |
Long-Term Price Volatility Vs. Market
How volatile is Savior Lifetec's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall St
Should You Use Savior Lifetec's (GTSM:4167) Statutory Earnings To Analyse It?1 month ago | Simply Wall St
Savior Lifetec (GTSM:4167) Seems To Use Debt Quite Sensibly2 months ago | Simply Wall St
Introducing Savior Lifetec (GTSM:4167), A Stock That Climbed 57% In The Last YearValuation
Is Savior Lifetec undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 4167 (NT$27.7) is trading below our estimate of fair value (NT$184.22)
Significantly Below Fair Value: 4167 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 4167 is poor value based on its PE Ratio (38.1x) compared to the TW Pharmaceuticals industry average (17.3x).
PE vs Market: 4167 is poor value based on its PE Ratio (38.1x) compared to the TW market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4167's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4167 is overvalued based on its PB Ratio (2.6x) compared to the TW Pharmaceuticals industry average (2x).
Next Steps
Future Growth
How is Savior Lifetec forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
15.9%
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 4167's forecast earnings growth is above the savings rate (0.8%).
Earnings vs Market: Insufficient data to determine if 4167's earnings are forecast to grow faster than the TW market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 4167's revenue (15.9% per year) is forecast to grow faster than the TW market (11.3% per year).
High Growth Revenue: 4167's revenue (15.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4167's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Savior Lifetec performed over the past 5 years?
41.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4167 has high quality earnings.
Growing Profit Margin: 4167 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 4167 has become profitable over the past 5 years, growing earnings by 41.5% per year.
Accelerating Growth: 4167 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 4167 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 4167's Return on Equity (6.3%) is considered low.
Next Steps
Financial Health
How is Savior Lifetec's financial position?
Financial Position Analysis
Short Term Liabilities: 4167's short term assets (NT$2.4B) exceed its short term liabilities (NT$554.7M).
Long Term Liabilities: 4167's short term assets (NT$2.4B) exceed its long term liabilities (NT$991.1M).
Debt to Equity History and Analysis
Debt Level: 4167's debt to equity ratio (18%) is considered satisfactory.
Reducing Debt: 4167's debt to equity ratio has reduced from 78.4% to 18% over the past 5 years.
Debt Coverage: 4167's debt is well covered by operating cash flow (43.8%).
Interest Coverage: 4167's interest payments on its debt are well covered by EBIT (7.9x coverage).
Balance Sheet
Next Steps
Dividend
What is Savior Lifetec current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4167's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 4167's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4167's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4167's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4167's dividend in 3 years as they are not forecast to pay a notable one for the TW market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
CEO
M. Ku
no data
Tenure
Dr. M. Sherry Ku, Ph.D. serves as the Chief Executive Officer at Savior Lifetec Corporation since 2014 and served as its Chairman since 2014 until 2018. Dr. Ku served as the Head of Early Pharmaceutical De...
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.
Top Shareholders
Company Information
Savior Lifetec Corporation's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Savior Lifetec Corporation
- Ticker: 4167
- Exchange: GTSM
- Founded: 2004
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$8.263b
- Shares outstanding: 298.30m
- Website: https://www.saviorlifetec.com.tw/en/
Number of Employees
Location
- Savior Lifetec Corporation
- 29, Ke-Jhong Road
- Chunan Chen
- Miaoli
- 35053
- Taiwan
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 4167 | GTSM (Taipei Exchange) | Yes | Common Stock | TW | TWD | Dec 2012 |
Biography
Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent fo...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/23 08:43 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.